Core Viewpoint - The company, Gongtong Pharmaceutical, reported a decline in revenue and net profit for the year 2024, indicating significant financial challenges compared to previous years [1][2]. Financial Performance Summary - In 2024, Gongtong Pharmaceutical achieved operating revenue of 537 million yuan, a decrease of 5.26% from 566 million yuan in 2023 [2]. - The net profit attributable to shareholders was -27.59 million yuan, a decline of 219.94% compared to a profit of 23 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses was -28.22 million yuan, down 234.61% from 20.96 million yuan in 2023 [2]. - The net cash flow from operating activities was -20.59 million yuan, a significant drop from 68.13 million yuan in the previous year, representing a decrease of 130.22% [2]. Q1 2025 Performance - In the first quarter of 2025, the company reported operating revenue of 139 million yuan, reflecting a year-on-year increase of 13.90% from 122 million yuan [3]. - The net profit attributable to shareholders for Q1 2025 was 1.08 million yuan, a decrease of 69.50% compared to 3.55 million yuan in the same period last year [3]. - The net profit after excluding non-recurring items was 1.34 million yuan, down 61.42% from 3.46 million yuan in Q1 2024 [3]. - The net cash flow from operating activities for Q1 2025 was -28.77 million yuan, worsening from -24.22 million yuan in the previous year [3]. Fundraising Activities - Gongtong Pharmaceutical raised a total of 238.96 million yuan from its public offering, with a net amount of 194.18 million yuan after deducting issuance costs [4]. - The company planned to raise 650 million yuan for production projects and working capital through its initial public offering [4]. - The total amount raised from two fundraising activities was 61.896 million yuan [5].